

Plasma derived medicinal products: production data



Plasma derived medicinal products play a key and often irreplaceable role in the treatment of many acute and chronic pathologies.

Some of the pathologies treated with plasma derived medicinal products

Congenital Immunodeficiencies
Neurological Diseases
Haemophilia and other congenital disorders of the coagulation
Cirrhosis and related complications



On an international level we can observe an increase in their use for:

The identification of new therapeutic indications;
The ageing of population;
The increase in the diagnoses in countries with emerging economies



Self-sufficiency rates of the plasma derived medicinal products

Products on a toll manufacturing basis within the current agreements. 2015 Data




MPD from National Plasma

The percentage next to each one shows the share of national requirements that is met through the Italian Plasma System.




MPD from Commercial Plasma

The remaining share derives from the purchase on the free market of products coming from plasma outside the country.



Plasma provided to the industry

comparison among Italy and the other European countries




2013 EDQM Data. A comparison among European and extra-European countries at the same socio-economical level, where plasma is collected through voluntary, periodic, responsible, anonymous and unpaid donations, shows that Italy has one of the highest contribution indexes: just Netherlands and Belgium have higher indexes.

(*) Countries where unpaid and paid donations coexist: Czech Republic and Germany.

Italian Plasma sent to the industry


2000 - 2016 Trend, values expressed in Kg



* Updated Data in April 2017

Trend of the plasma production for the delivery to the industry. 2020 Target.

Values expressed in Kg



Plasma derived from Apheresis (Yellow) Plasma derived from Decomposition (Blue)

In the period between 2016 and 2020, in light of the constant trend in the quantity of plasma that will be collected in Italy, thanks also to the implementation of the Patient Blood Management's practices, the national and regional planning foresees the increase of apheresis procedures.